Major Depressive Disorder Medication Use Strategies and Analyses

Authors

  • Huimin Song School of Public Health, University at Albany, State University of New York, Albany, USA

DOI:

https://doi.org/10.54097/jpnk8c69

Keywords:

Major Depressive Disorder (MDD), SSRIs, SNRIs, novel antidepressants.

Abstract

Major depressive disorder (MDD) is a pressing mental health problem globally. Under the contemporary era, significant progress has been achieved in understanding the pathogenic mechanisms of MDD. Pharmacotherapy, especially SSRIs, works as the most frequent option in MDD treatment. To identify a molecule with prompt effectiveness and minimal adverse effects is the overarching objective, but the mechanisms underlying the therapeutic effects in the MDD treatment remain nuanced and are not completely revealed. This literature review describes mechanisms, clinical trials conducted, therapeutic benefits along with adverse effects discovered of several key antidepressants, and aims to provide insights into the future antidepressant discovery, development and application. SSRIs together with SNRIs have acute effects on the monoaminergic system, but their strength is subject to limitations imposed by delayed or inadequate therapeutic efficacy, suboptimal remission outcomes, and adverse reactions. Consequently, novel and more efficacious antidepressant therapeutic agents are identified and developed. The review covers the recent clinical findings of a few promising antidepressants, and found that rapid-acting, oral administration, and substantial benefits in both remission and response are optimal features for antidepressants. Taken together, further explorations into both the pharmacological and pathophysiological mechanisms remain necessary. Future studies regarding the assessments of prolonged therapeutic benefits, safety profiles, recognitions of novel biomarkers among MDD patients especially with substance use disorders and/or treatment-resistant depression are also essential.

Downloads

Download data is not yet available.

References

[1] Fries GR., Saldana VA., Finnstein J., Rein T. Molecular pathways of major depressive disorder converge on the synapse. Molecular Psychiatry, 2022, 28(1): 284-297. doi: 10.1038/s41380-022-01806-1 DOI: https://doi.org/10.1038/s41380-022-01806-1

[2] Daskalakis NP., Meijer OC., Kloet ER. Mineralocorticoid receptor and glucocorticoid receptor work alone and together in cell-type-specific manner: Implications for resilience prediction and targeted therapy. Neurobiology of Stress, 2022, 18(100455). https://doi.org/10.1016/j.ynstr.2022.100455 DOI: https://doi.org/10.1016/j.ynstr.2022.100455

[3] Pérez MGS., Jiménez Y., Bagán L., Bagán JV. Oral side effects of fluoxetine in patients with depressive disorder: A systematic review. Oral Medicine and Pathology, 2025, 30(3): 373-382. DOI: https://doi.org/10.4317/medoral.26947

[4] Xie Z., Gao Z., Li X., Li S., Tang F., Zhang C. Sertraline and inflammatory markers in major depression: a systematic review and meta-analysis. Annals of General Psychiatry, 2025, 24(53). DOI: https://doi.org/10.1186/s12991-025-00596-4

[5] Strawn JR., Mills JA., Poweleit EA., Ramsey LB., Croarkin PE. Adverse Effects of Antidepressant Medications and their Management in Children and Adolescents. Pharmacotherapy, 2023, 43(7): 675-690. DOI: https://doi.org/10.1002/phar.2767

[6] Arterburn D., Sofer T., Boudreau DM., Bogart A., Westbrook EO., Theis MK., Simon G., Haneuse S. Long-Term Weight Change after Initiating Second-Generation Antidepressants. Journal of Clinical Medicine, 2016, 5(4). doi: 10.3390/jcm5040048 DOI: https://doi.org/10.3390/jcm5040048

[7] Edinoff AN., Akuly HA., Hanna TA., Ochoa CO., Patti SJ., Ghaffar YA., Kaye AD., Viswanath O., Urits I., Boyer AG., Cornett EM., Kaye AM. Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review. Neurology International, 2021, 13(3): 387-401. doi:10.3390/neurolint13030038 DOI: https://doi.org/10.3390/neurolint13030038

[8] Fagiolini A., Cardoner N., Pirildar S., Ittsakul P., Ng B., Duailibi K., El Hindy N. Moving from serotonin to serotonin-norepinephrine enhancement with increasing venlafaxine dose: clinical implications and strategies for a successful outcome in major depressive disorder. Expert Opinion on Pharmacotherapy, 2023, 24(15): 1715–1723. https://doi.org/10.1080/14656566.2023.2242264 DOI: https://doi.org/10.1080/14656566.2023.2242264

[9] Kishi T., Ikuta T., Sakuma K., Okuya M., Hatano M., Matsuda Y., Iwata N. Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis. Molecular Psychiatry, 2022, 28(1): 402-409. doi: 10.1038/s41380-022-01824-z DOI: https://doi.org/10.1038/s41380-022-01824-z

[10] Calvi A., Fischetti I., Verzicco I., Murri MB., Zanetidou S., Volpi R., Coghi P., Tedeschi S., Amore M., Cabassi A. Antidepressant Drugs Effects on Blood Pressure. Frontiers Cardiovascular Medicine, 2021, 8(704281). doi: 10.3389/fcvm.2021.704281. DOI: https://doi.org/10.3389/fcvm.2021.704281

[11] Fraile-Martinez O., Garcia-Montero C., Alvarez-Mon MA., Ortega MA., Alvarez-Mon M., Quintero J. Delving into the Perception, Use, and Context of Duloxetine in Clinical Practice: An Analysis Based on the Experience of Healthcare Professionals. Brain Sciences, 2025, 15(7). doi:10.3390/brainsci15070757 DOI: https://doi.org/10.3390/brainsci15070757

[12] Pillinger T., Arumuham A., McCutcheon RA., D’Ambrosio E., Basdanis G., Branco M. The effects of antidepressants on cardiometabolic and other physiological parameters: a systematic review and network meta-analysis. The Lancet, 2025, 406(10515): 2063-2077. DOI: https://doi.org/10.1016/S0140-6736(25)01293-0

[13] Kim J., Suzuki K., Kavalali ET., Monteggia LM. Ketamine: Mechanisms and Relevance to Treatment of Depression. Annual Review of Medicine, 2024, 75: 129-143. DOI: https://doi.org/10.1146/annurev-med-051322-120608

[14] Bozzatello P., Novelli R., Schisano R., Brasso C., Rocca P., Bellino S. New Agents in the Treatment of Psychiatric Disorders: What Innovations and in What Areas of Psychopathology? Pharmaceuticals, 2025, 18(5). doi:10.3390/ph18050665 DOI: https://doi.org/10.3390/ph18050665

[15] McCarthy B., Bunn H., Santalucia M., Wilmouth C., Muzyk A., Smith CM. Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder. Clinical Psychopharmacology and Neuroscience, 2023, 21(4): 609-616. doi: 10.9758/cpn.23.1081 DOI: https://doi.org/10.9758/cpn.23.1081

Downloads

Published

15-11-2026

Issue

Section

Articles

How to Cite

Song, H. (2026). Major Depressive Disorder Medication Use Strategies and Analyses. International Journal of Biology and Life Sciences, 17(2), 102-107. https://doi.org/10.54097/jpnk8c69